143 related articles for article (PubMed ID: 26548560)
21. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
22. Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells in vitro by blocking multiple kinase pathways.
Sun C; Yang X; Jin Z; Gao Z
J Chemother; 2023 May; 35(3):259-269. PubMed ID: 35731713
[TBL] [Abstract][Full Text] [Related]
23. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
[TBL] [Abstract][Full Text] [Related]
24. Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion.
Gupta S; Hau AM; Beach JR; Harwalker J; Mantuano E; Gonias SL; Egelhoff TT; Hansel DE
PLoS One; 2013; 8(11):e81081. PubMed ID: 24312263
[TBL] [Abstract][Full Text] [Related]
25. Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.
Ono A; Oike R; Okuhashi Y; Takahashi Y; Itoh M; Nara N; Tohda S
Anticancer Res; 2013 Mar; 33(3):809-13. PubMed ID: 23482748
[TBL] [Abstract][Full Text] [Related]
26. Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.
Zhang J; Jiang W; Liu W; Wu JJ; Song L; Cheng JX; Yao M; Yang LP; Yao DF
Future Oncol; 2016 Feb; 12(4):515-24. PubMed ID: 26776341
[TBL] [Abstract][Full Text] [Related]
27. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.
Hoang B; Benavides A; Shi Y; Yang Y; Frost P; Gera J; Lichtenstein A
J Biol Chem; 2012 Jun; 287(26):21796-805. PubMed ID: 22556409
[TBL] [Abstract][Full Text] [Related]
28. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
Ravichandran K; Zafar I; Ozkok A; Edelstein CL
Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
[TBL] [Abstract][Full Text] [Related]
29. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
30. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
[TBL] [Abstract][Full Text] [Related]
31. IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway.
Chen S; Han Q; Wang X; Yang M; Zhang Z; Li P; Chen A; Hu C; Li S
Cell Death Dis; 2013 Oct; 4(10):e842. PubMed ID: 24113176
[TBL] [Abstract][Full Text] [Related]
32. Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication.
Kuss-Duerkop SK; Wang J; Mena I; White K; Metreveli G; Sakthivel R; Mata MA; Muñoz-Moreno R; Chen X; Krammer F; Diamond MS; Chen ZJ; García-Sastre A; Fontoura BMA
PLoS Pathog; 2017 Sep; 13(9):e1006635. PubMed ID: 28953980
[TBL] [Abstract][Full Text] [Related]
33. F-actin rearrangement is regulated by mTORC2/Akt/Girdin in mouse fertilized eggs.
Wu D; Yu D; Wang X; Yu B
Cell Prolif; 2016 Dec; 49(6):740-750. PubMed ID: 27666957
[TBL] [Abstract][Full Text] [Related]
34. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
[TBL] [Abstract][Full Text] [Related]
36. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.
Kim EK; Yun SJ; Ha JM; Kim YW; Jin IH; Yun J; Shin HK; Song SH; Kim JH; Lee JS; Kim CD; Bae SS
Oncogene; 2011 Jun; 30(26):2954-63. PubMed ID: 21339740
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
[TBL] [Abstract][Full Text] [Related]
38. mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice.
Sun J; Liu Y; Tran J; O'Neal P; Baudry M; Bi X
Cell Mol Life Sci; 2016 Nov; 73(22):4303-4314. PubMed ID: 27173058
[TBL] [Abstract][Full Text] [Related]
39. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
[TBL] [Abstract][Full Text] [Related]
40. mTORC2 activation is regulated by the urokinase receptor (uPAR) in bladder cancer.
Hau AM; Leivo MZ; Gilder AS; Hu JJ; Gonias SL; Hansel DE
Cell Signal; 2017 Jan; 29():96-106. PubMed ID: 27777073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]